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Since its inception in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria 
(the Global Fund) has disbursed over $39 billion across 120 countries. Funding 
provided by donors, mainly the United States (USA), France, United Kingdom (UK), 
Germany, and Japan, has undoubtedly affected the lives of millions of people. And as 
the Global Fund approaches its Sixth replenishment — to be held in France in October 
2019 — the recently published results report appears to make a compelling case for 
further investment.1  
On the report cover (see figure 1), a headline proclaims “27 Million Lives Saved”— 
over three times the population of Switzerland. Since its publication, this striking figure 
has been repeated and amplified by advocacy groups2–4 and within mainstream news 
reporting.5–7 In the UK, an online application even allows users to calculate the number 
of lives saved by a specific constituency, drawing a direct line between UK funding for 
the Global Fund and a proportionate share of lives saved.8 
At a time when aid scepticism is on the rise and aid budgets are under pressure, the 
Global Fund is smart to emphasize the health returns on investment from donor 
contributions. Yet, for these claims to be genuinely helpful to donor governments, 
which must choose between further investment in the Global Fund and competing uses 
of scarce financial resources, including for bilateral programmes for HIV, malaria, and 
tuberculosis, whilst also convincing their increasingly questioning voters and national 
media, they must accurately, rigorously, and transparently reflect the Global Fund’s 
own contribution to global progress. So, how seriously should donor governments take 
these numbers? Are funded programmes offering the best possible value for money? 
How does the Global Fund stack up against other aid investments — many of which 
will also undergo replenishments within the next two years (see figure 2)?9  
All the partners… 
Examining publicly available documents,1 it is our judgment that the Global Fund’s 
claims are not sufficiently supported by available evidence. Most glaring is the question 
of attribution. In its results reporting and communication materials, the Global Fund 
                                                        
1
 Results reports from previous years are no longer available through the Global Fund website, making 
it difficult to compare this methodology/document to previous iterations. 
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conflates two ideas about its own nature. First, the Global Fund is presented as a 
partnership, encompassing every funder, government, non-governmental organisation, 
implementer and private actor involved in treating or preventing the three diseases in 
eligible countries. And second, the Global Fund operates as a standalone funding 
instrument with a roughly $4 billion annual budget. The results reporting explicitly 
takes credit for the accomplishments of the partnership, including bilateral mechanisms 
like the President’s Emergency Plan for AIDS Relief and the President’s Malaria 
Initiative,10,11 plus domestic government investments. Yet, the replenishment will 
advocate for investment in the Global Fund as a funding instrument¸ attracting 
resources that could otherwise be channelled elsewhere in the partnership through 
alternative bilateral or multilateral mechanisms. How can results reporting without 
direct attribution to the Global Fund as a standalone institution support continued 
institutional investment? And with domestic resources in particular growing faster than 
development assistance for some priority conditions such as HIV/AIDS,12 attribution 
across all payers — national, international, public, and private — becomes even more 
difficult to justify.2 
… all the interventions… 
Moreover, the methodology for calculating lives saved is opaque and problematic. The 
Global Fund released a one-page “Note on Methodology” within the 2018 results 
report; the lives saved figure, they claim, is estimated using “the most advanced 
modelling methods currently available” based on “widely accepted data sources”. We 
are told only that the number of lives saved was calculated as the difference between 
the actual number of deaths and the expected number of deaths absent any intervention. 
The counterfactual against which impact is measured is a hypothetical scenario in 
which all activities for HIV treatment and prevention, malaria control, and tuberculosis 
control stopped abruptly in 2000. Again, this method is likely to overstate the impact 
of Global Fund investments per se, explicitly taking credit for all interventions to 
address the three diseases in its remit — including in large countries like India and 
South Africa, which have made significant domestic investments in tuberculosis and 
HIV, respectively. While exact shares will depend on the health outcome under 
consideration, economic growth alone is estimated to be responsible for about half of 
maternal and child mortality reduction between 1990 and 2010,13 so taking credit for 
the entirety of mortality reduction is misleading at the least. No further information is 
provided regarding the model assumptions, methods, limitations, or uncertainty; point 
estimates are presented without accompanying confidence intervals. 
…and all the (right) data 
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 The transition to a key performance indicator (KPI) framework based primarily on a “contribution” (vs. 
attribution) approach was approved by the Global Fund Board in June 2016 for the 2017-2022 strategy 
period. In Board discussions in 2017, the Secretariat noted that “The Global Fund moved to reporting of 
full national results under the 2017-2022 KPI framework, to take a more holistic view of performance. 
The challenge is that national performance reflects collective efforts, not just those of the Global Fund. 
Information about Global Fund support, compared to other donors, will help with more accurate 
performance evaluation.”26 The 2018 results report presents the breakdown of funding sources (Global 
Fund vs. domestic and other donors) for specific highlighted countries and reports the overall 
contribution of Global Fund financing among all international (but not domestic) financing for each of 
the three diseases. However, it does not adjust or scale national results vis-à-vis the Global Fund-specific 
contribution. 
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In many countries where vital statistic systems are weak or non-existent, different 
sources of data, which may take the form of published studies, demographic and health 
surveys, or modelled global health estimates, will often give vastly different results and 
hence much varying impact estimates.14 Therefore, it is unrealistic to assume that 
mortality estimates by disease and comorbidity are available, up to date, and reliable, 
(i.e., tuberculosis patients with a positive smear test who die from tuberculosis as per 
the Global Fund methods note).  
The Global Fund’s methodology is unclear, unverifiable, and unreproducible. If the 
modelling exercise is as rigorous as the Global Fund claims — and the data are indeed 
drawn from appropriate and sufficient sources — its methods and underpinning raw 
data should be released and subjected to public scrutiny, the cornerstone of a transparent 
and scientifically rigorous process. Sharing its data repositories and methods, which 
were presumably sourced and synthesised using public monies, would also qualify as a 
valuable contribution to the global public good, as it will allow further policy-relevant 
research that is much needed by funders, development partners, academia, and recipient 
country governments. 
But we would not stop there. The process followed to commission the analyses, 
including those who carried them out (i.e., especially if external to the Global Fund), 
also ought to be transparent and shared. Those involved should declare any conflicts of 
interest and invite a debate on methods, data, and findings, ideally within peer-reviewed 
literature, to ensure some degree of quality assurance. Such an approach will ultimately 
strengthen confidence in the Global Fund as an institution when making the case for re-
investment. 
Saving the same life twice? 
The Global Fund is not alone in proffering questionable methods to argue for sustained 
donor investments — and its approach becomes even more problematic when other 
global health funders generate their own estimates of lives saved using similar 
methodologies. Recently, an editorial in The Lancet suggested problems with the 
investment case for the World Health Organization (WHO); the authors highlight a 
clear disconnect between the WHO’s specific activities and budgetary request (i.e., 
$14.1 billion over five years) and grand claims about the potential global impact of 
Universal Health Coverage (UHC), based on total investment of over $1 trillion.15 
Likewise, a recent BMJ analysis claims that a full Global Financing Facility (GFF) 
replenishment ($2.6 billion) could save up to 34.7 million lives. On a close read, 
however, it becomes apparent that these projected results encompass the activities of 
the entire GFF partnership — apparently also including results achieved by Gavi, and 
the Global Fund, among others. The specific relationship between institutional 
investment in the GFF and impact of the broader partnership remains unclear.16 Each 
entity claims to save many of the very same lives, making it difficult to distinguish 
comparative advantage or the investment case for each funding, or technical assistance 
instrument.  
A Question of Evidentiary Standards 
As these and other multilaterals approach donors to refill their coffers, contributor 
governments must scrutinise these claims and assess whether their taxpayers’ money 
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has been and will be put to good use. But what should the evidential and governance 
standards be for making a case for more money and for holding those spending this 
money accountable? For the health care sector at least, should the standards match those 
used by the National Institute for Health and Care Excellence in the UK to allocate 
millions of pounds to the latest cancer drug?17 Should they equal academic research 
standards for publication in peer-reviewed journals? Or, perhaps, should they be 
consistent with widely accepted principles of good programme evaluation set out by 
the International Initiative for Impact Evaluation (3ie)?18 And with regard to due 
processes, should the Global Fund — and other multilateral institutions entrusted with 
large sums of public money — commit to the Open Government principles with respect 
to the methods and data used to assess project impact?19  
It is hard to argue that every global health funder, or agency should carry out impact 
evaluation that would allow for attribution for the entirety of its portfolio; as funders’ 
activities are naturally complementary, efforts to tease out attributable impact of small 
investments or technical assistance can be an exercise in futility. Yet, modelled results 
can never fully substitute for empirically verified evaluation, especially when assessing 
past results. Use of modelling is ubiquitous (and often quite useful); nonetheless, at 
least some other funders either commission, or can point to rigorous studies that support 
modelled claims with attributable impact.20–23 Countries that receive hundreds of 
millions of dollars from the Global Fund should also be able to empirically demonstrate 
that Global Fund investments have indeed led to health improvements, or at the very 
least attributable supply chain performance or service delivery — without relying 
wholly on theoretical, modelled results.24  
Good intentions are not enough… 
With the replenishment forthcoming, we need robust evidence of impact and due 
process, or we risk empowering the sceptics and compromising the good work of the 
Global Fund and aid in general. But most importantly, we urge major actors publicly to 
acknowledge uncertainty in the evidence base underpinning the estimates of their own 
impact — and to open a robust, frank, and respectful public dialogue about the strength 
of the evidence. In low- and middle-income countries, uncertainty is unavoidable — 
driven by incomplete death registration data, weak or no evidence of comparative 
effectiveness of alternative treatments, and a lack of reliable routinely collected billing 
information to estimate health care resource use, all of which are a given in high-income 
country settings. Estimates of impact will be more powerful and convincing if they are 
open to public scrutiny and include clear caveats about this uncertainty, coupled with a 
call for further investment in evidence and data generation. Perhaps, a donor and 
development industry-independent (and very public) Aid Fact Checker service could 
encourage both more moderation in pronouncing impact and more systematic evidence 
generation to back such pronouncements.  
We believe that a more nuanced approach would be more honest and possibly more 
effective in securing funds for global health relief. And for low- and middle-income 
countries facing transition from aid dependence25 and daunting shortfalls in their 
domestic health care budgets, showing that evidence-informed advocacy for health can 
raise billions would perhaps send the most powerful message of all.  
 
 5 
Acknowledgements 
We would like to thank Claire Melamed, Ruth Levine and Owen Barder for useful 
discussions on incentivising better measurement and reporting of impact. We are also 
grateful to the three anonymous peer reviewers for their helpful comments and 
suggestions. 
The authors received no funding for this study. RF acting as corresponding author had 
the final responsibility for the decision to submit for publication.  
Author contributions 
RF and KC developed the idea, all authors made a significant contribution to the 
development and write up of this article. 
Declaration of interest 
No interests to declare. 
Ethics 
This article requires no ethical clearance. 
 
References 
1 The Global Fund. Results Report 2018. 2018 DOI:10.1242/dmm.009662. 
2 Ryan K. The results are in: The Global Fund has saved 27 million lives! One. 
2018. https://www.one.org/us/2018/09/17/global-fund-saved-27-million-lives/ 
(accessed Oct 3, 2018). 
3 Fight F of the G. 27 Million Lives Saved Through Global Fund-Supported 
Programming. Friends Glob. Fight. 2018. https://www.theglobalfight.org/27-
million-lives-saved/ (accessed Oct 3, 2018). 
4 Global Funds Advocates Network. Global Fund Results Report. 2018. 
5 AFP. ‘Global AIDS, TB fight needs more money’. New Vis. 2018. 
https://www.newvision.co.ug/new_vision/news/1485650/global-aids-tb-fight-
money (accessed Oct 3, 2018). 
6 AFP. Global AIDS, TB fight needs more money: health fund. Fr. 24. 2018. 
7 Sulcas A. SA shows what is possible in fighting killer diseases. Bus. Day. 
2018. https://www.businesslive.co.za/bd/opinion/2018-09-19-sa-shows-what-
is-possible-in-fighting-killer-diseases/ (accessed Oct 3, 2018). 
8 Lifes Saved Through The Global Fund. STOPAIDS. . 
9 Morris S, Lu J, Fisher-Post C. Mapping the Concessional Financing 
Landscape : Key Data on the Role of Multilateral Institutions and Funds 2019-
2020 Replenishments Overview. 2018; : 1–23. 
 
 6 
10 The United State President’s Emergency Plan For AIDS Relief. 15 YEARS OF 
SAVING LIVES THROUGH AMERICAN GENEROSITY AND 
PARTNERSHIPS. https://www.pepfar.gov (accessed Oct 3, 2018). 
11 President’s Malaria Initiative. Fighting Malaria and Saving Lives. 
https://www.pmi.gov/about (accessed Oct 3, 2018). 
12 Dieleman JL, Haakenstad A, Micah A, et al. Spending on health and 
HIV/AIDS: domestic health spending and development assistance in 188 
countries, 1995–2015. Lancet 2018; 391: 1799–829. 
13 Bishai DM, Cohen R, Alfonso YN, Adam T, Kuruvilla S, Schweitzer J. Factors 
Contributing to Maternal and Child Mortality Reductions in 146 Low- and 
Middle-Income Countries between 1990 and 2010. PLoS One 2010; 11: 1–13. 
14 Boerma T, Victora C, Abouzahr C. Monitoring country progress and 
achievements by making global predictions: is the tail wagging the dog? Lancet 
2018; 392: 607–9. 
15 Collier P. The case for investing in WHO. Lancet 2018; 392: 1–4. 
16 Chou VB, Bubb-humfryes O, Sanders R, et al. Pushing the envelope through 
the Global Financing Facility: potential impact of mobilizing additional support 
to scale-up life-saving interventions for women, children and adolescents in 50 
high-burden countries Victoria. BMJ Glob Heal 2018; October. 
17 The National Institute for Health and Care Excellence. Improving health and 
social care through evidence-based guidance. https://www.nice.org.uk 
(accessed Oct 3, 2018). 
18 International Initiative for Impact Evaluation (3ie). Principles for Impact 
Evaluation. 2015; : 1–2. 
19 Partnership OG. Promoting Democracy, Improving Governance, Renewing 
Trust. https://www.opengovpartnership.org (accessed Oct 3, 2018). 
20 Gertler PJ, Giovagnoli P, Martinez S. Rewarding provider performance to 
enable a healthy start to life: evidence from Argentina’s Plan Nacer. 2014 
DOI:10.1596/1813-9450-6884. 
21 Birdthistle I, Schaffnit SB, Kwaro D, et al. Evaluating the impact of the 
DREAMS partnership to reduce HIV incidence among adolescent girls and 
young women in four settings: A study protocol. BMC Public Health 2018; 18: 
1–15. 
22 Bendavid E, Holmes C, Bhattacharya J, Miller G. HIV Development 
Assistance and Adult Mortality in Africa. JAMA 2012; 307: 2060–7. 
23 Jakubowski A, Stearns SC, Kruk ME, Angeles G, Thirumurthy H. The US 
President’s Malaria Initiative and under-5 child mortality in sub-Saharan 
Africa: A difference-in-differences analysis. PLoS Med 2017; 14: 1–20. 
24 Glassman A, Fan V, Over M. More Health for the Money. 2013 
DOI:10.1016/j.parint.2011.08.011. 
25 Silverman R. Projected Health Financing Transitions: Timeline and Magnitude. 
Washington, DC, 2018. 
26 The Global Fund 37th Board Meeting. Kigali 
https://www.theglobalfund.org/media/6971/bm37_meeting_report_en.pdf. 
 7 
Figure legends 
Figure 1: The Global Fund Results Report 2018 
Figure 2: Multilateral Concessional Lender Replenishment Timeline Through 2020 
